Outlook Therapeutics
OTLK
$8.50
Share price
-4.71%
Change (1 day)
626.50%
Change (1 year)
Categories
Outlook Therapeutics (OTLK) - Cash on Hand
Cash on Hand as of December 2023 : $10.35 M
According to Outlook Therapeutics
's latest financial reports the company has $10.35 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Outlook Therapeutics - Cash on Hand chart (from 2015 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-09-30 | $23.39 M | 34.46% |
| 2022-09-30 | $17.39 M | 20.17% |
| 2021-09-30 | $14.47 M | 15.49% |
| 2020-09-30 | $12.53 M | 56.4% |
| 2019-09-30 | $8.01 M | 366.73% |
| 2018-09-30 | $1.71 M | -46.09% |
| 2017-09-30 | $3.18 M | 35.45% |
| 2016-09-30 | $2.35 M | -74.07% |
| 2015-09-30 | $9.07 M | 0% |
| 2014-09-30 | $9.07 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | $5.29 M | -48.87% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | $0.12 B | 1,110.95% | 🇬🇧 UK |
 Novavax NVAX | $0.56 B | 5,389.30% | 🇺🇸 USA |
 Novocure
NVCR | $0.91 B | 8,692.62% | Jersey |